Table 4.
Prognostic value of Metrnβ as a new biomarker for HF patients
All-cause deathCardiovascular death
HR95% CIP valueHR95% CIP value
Age, yr 1.06 1.04–1.07 <0.001 1.05 1.03–1.07 <0.001 
Female 0.69 0.48–0.99 0.041 0.86 0.67–1.49 0.600 
ZLog (Metrnl) 1.18 1.01–1.37 0.038 1.12 1.08–1.71 0.008 
LVEF 1.01 1.00–1.02 0.191 1.00 0.99–1.02 0.720 
Ischemia 1.07 0.79–1.46 0.646 1.70 1.10–2.65 0.018 
Diabetes 1.33 0.99–1.80 0.062 1.26 0.82–1.93 0.300 
Hypertension 1.06 0.75–1.48 0.758 1.03 0.62–1.71 0.920 
Quartile   
Age, yr 1.05 1.04–1.07 <0.001 1.05 1.23–1.68 0.001 
Female 0.69 0.48–0.99 0.043 1.00 0.97–1.02 0.650 
ZLog (Metrnl) 1.26 1.09–1.45 0.002 1.46 1.23–1.68 0.001 
LVEF 1.01 1.00–1.02 0.171 0.86 0.31–1.41 0.600 
Ischemia 1.06 0.78–1.44 0.711 1.66 1.21–2.11 0.027 
Diabetes 1.32 0–98–1.77 0.072 1.25 0.83–1.66 0.310 
Hypertension 1.03 0.73–1.44 0.875 0.98 0.48–1.47 0.920 
All-cause deathCardiovascular death
HR95% CIP valueHR95% CIP value
Age, yr 1.06 1.04–1.07 <0.001 1.05 1.03–1.07 <0.001 
Female 0.69 0.48–0.99 0.041 0.86 0.67–1.49 0.600 
ZLog (Metrnl) 1.18 1.01–1.37 0.038 1.12 1.08–1.71 0.008 
LVEF 1.01 1.00–1.02 0.191 1.00 0.99–1.02 0.720 
Ischemia 1.07 0.79–1.46 0.646 1.70 1.10–2.65 0.018 
Diabetes 1.33 0.99–1.80 0.062 1.26 0.82–1.93 0.300 
Hypertension 1.06 0.75–1.48 0.758 1.03 0.62–1.71 0.920 
Quartile   
Age, yr 1.05 1.04–1.07 <0.001 1.05 1.23–1.68 0.001 
Female 0.69 0.48–0.99 0.043 1.00 0.97–1.02 0.650 
ZLog (Metrnl) 1.26 1.09–1.45 0.002 1.46 1.23–1.68 0.001 
LVEF 1.01 1.00–1.02 0.171 0.86 0.31–1.41 0.600 
Ischemia 1.06 0.78–1.44 0.711 1.66 1.21–2.11 0.027 
Diabetes 1.32 0–98–1.77 0.072 1.25 0.83–1.66 0.310 
Hypertension 1.03 0.73–1.44 0.875 0.98 0.48–1.47 0.920 

Multivariable analysis of cohort data of HF patients was performed following the Fine and Gray method from R essentials for SPSS. Values of Metrnβ were available for all patients and were log-transformed. ZLog, log-transformed and per 1 SD.

or Create an Account

Close Modal
Close Modal